PREVALENCE AND ASSOCIATED FACTORS OF COGNITIVE IMPAIRMENT IN PATIENTS WITH SCHIZOPHRENIA AT SOMDET CHAOPRAYA INSTITUTE OF PSYCHIATRY
Keywords:
prevalence, related factors, patients with schizophrenia, cognitive impairmentAbstract
Abstract
Objectives: 1) To examine the prevalence of cognitive impairment in patients with schizophrenia, 2) To explore the characteristics of cognitive impairment, and 3) To identify associated factors contributing to cognitive impairment in this population.
Material and Methods: This analytical cross-sectional included 130 outpatients with schizophrenia at Somdet Chaopraya Institute of Psychiatry who met the inclusion and exclusion criteria. The assessment tools consisted of 1) a demographic questionnaire, 2) the Thai version of Montreal Cognitive Assessment (MOCA) and 3) the Vienna Test System. Descriptive statistics, Chi-square tests, and logistic regression analysis were used to analyses with statistically significant level of 0.05.
Results: The prevalence of cognitive impairment was 58.5%. Domain of impairment included attention, memory, executive functions, and processing speed. The significant protective factors against cognitive impairment included education level: lower or upper secondary school (adjusted OR = 0.052; 95%CI = 0.006, 0.427), and bachelor’s degree or higher (adjusted OR = 0.065; 95%CI = 0.007, 0.562). In addition, receiving trihexyphenidyl was associated with higher risk of cognitive impairment (adjusted OR = 3.097; 95%CI = 1.178, 8.140).
Conclusion: Higher education levels were protective factors against cognitive impairment, whereas the use of anticholinergic drugs was identified as a risk factor.
References
Lortrakul M, Sukanich P. Textbook of Ramathibodi psychiatry. 3rd ed. Bangkok: Beyond Enterprise; 2009.
Phanthunane P, Vos T, Whiteford H, Bertram M, Udomratn P. Schizophrenia in Thailand: prevalence and burden of disease. Popul Health Metr 2010; 8: 24-35.
Gubman GD, Tessler RC. The impact of mental illness on families. J Fam Issues 1987; 8(2): 226-45.
Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 2007; 64(5): 532-42.
มุทิตา พนาสถิตย์, นันทิกา ทวิชาชาติ, พวงสร้อย วรกุล. ภาวะพุทธิปัญญาของผู้ป่วยโรคจิตเภทเรื้อรังที่เข้ารักษาแบบผู้ป่วยนอก แผนกจิตเวช โรงพยาบาลจุฬาลงกรณ์. จุฬาลงกรณ์เวชสาร 2551; 52(1): 1-15.
Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S. Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004; 56(5): 301-7.
Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009; 23(3): 315-36.
Arunpongpaisal S, Sangsirilak A. Using MoCA-Thai to evaluate cognitive impairment in patients with schizophrenia. Journal of the Medical Association of Thailand 2013; 96(7): 860-5.
Gil D, Bengochea R, Arrieta M, Lastra I, Sánchez R, Álvarez A. Use of Barcelona Test for cognitive assessment of patients with schizophrenia. Actas Esp Psiquiatr 2008; 36(6): 337-44.
Squibb SM, Palmer BW, Paulsen JS, Jeste DV, Heaton RK. The Prevalence of Specific Cognitive Impairments in Schizophrenia. Arch Clin Neuropsychol 1997; 12(4): 409.
Mascio A, Stewart R, Botelle R, Williams M, Mirza L, Patel R, et al. Cognitive Impairments in Schizophrenia: A Study in a Large Clinical Sample Using Natural Language Processing. Front Digit Health 2021; 3: 711941.
Deneil WW. Biostatistics: A foundation of analysis in the health science. 6th ed. New Jersey: John Wiley & Sons, Inc; 1995.
Hemrungrojn S. MoCA Thai version Bangkok: MoCA Test. [online]. Available from: http://www.mocatest.org. [2023 Sep 17].
Bozikas VP, Kosmidis MH, Kiosseoglou G, Karavatos A. Neuropsychological profile of cognitively impaired patients with schizophrenia. Compr Psychiatry 2006; 47(2): 136-43.
Chan RCK, Chen EYH. Assessment of executive function for schizophrenia in Hong Kong. Hong Kong J Psychiatry 2005; 15(1): 23-8.
Joshi YB, Thomas ML, Braff DL, Green MF, Gur RC, Gur RE, et al. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia. Am J Psychiatry 2021; 178(9): 838-47.
Georgiou R, Lamnisos D, Giannakou K. Anticholinergic Burden and Cognitive Performance in Patients with Schizophrenia: A Systematic Literature Review. Front Psychiatry 2021; 12: 779607.
Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM, et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry 2010; 167(2): 160-9.
Goonathilake P, Ediriweera D, Ruban R, Isuru A. Prevalence and correlates of cognitive impairment in schizophrenia: a cross-sectional study from a teaching hospital southern Sri Lanka. BMC Psychiatry 2022; 22(1): 716.
McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry 2023; 28(5): 1902-18.
Vemuri P, Lesnick TG, Przybelski SA. Association of lifetime intellectual enrichment with cognitive decline in the older population. JAMA Neurol 2014; 71(8):1017-24.
Lee WJ, Liang CK, Peng LN. Protective factors against cognitive decline among community-dwelling middle-aged and older people in Taiwan: A 6-year national population-based study. Geriatr Gerontol Int 2017; 17: 20-7.
Sathienluckana T, Unaharassamee W, Suthisisang C, Suanchang O, Suansanae T. Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department. Integr Pharm Res Pract 2018; 7: 161-71.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Somdet Chaopraya Institute of Psychiatry
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles published are copyright of Journal of Somdet Chaopraya Institute of Psychiatry.
